REGENERON AXOKINE AND BDNF THERAPIES ARE FOCUS OF NEW R&D STRATEGY
REGENERON AXOKINE AND BDNF THERAPIES ARE FOCUS OF NEW R&D STRATEGY in the wake of the company's decision June 23 to discontinue Phase III clinical trials of its ciliary neurotrophic factor for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). As part of its "revised strategic direction" Regeneron will also concentrate on neurotrophin-3 (NT- 3), combinations of neurotrophic factors and a ligand discovery program.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth